TRU-SENTIMENT · DeltaNeutral
SYRE Trading Analysis - 10/15/2026 03:54 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
SYRE (Spyre Therapeutics Inc. Common Stock) at $79.35. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $0 vs put $1,940. RSI 38.1.
- Symbol
- SYRE
- Price
- $79.35
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-10-15 15:54:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options):Options flow via tru-sentiment methodology (Delta 40-60 only):
Call Volume: $0 (0.0%) Put Volume: $1,940 (100.0%) Total: $1,940
Sentiment is Bearish. Pure directional conviction shows 0 call trades, 2 put trades (4 contracts). Near-term expectation is downside or defensive positioning. Divergence: minute bars show minor stabilization ($78.51 to $79.35) yet options show only bearish puts — sentiment leads price weakness.
Key Statistics: SYRE
Fundamental Snapshot
Valuation
| P/E (trailing) | 1.70 |
| EPS (trailing 12 mo) | $-2.17 |
| Market cap | $7.43B |
| Shares outstanding | 93.5M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.99 |
| 52-week low | $21.01 |
| 52-week high | $110.17 |
| Historical volatility | 60.6% |
Ownership & trading
| Institutional ownership | 67.3% |
| Average daily volume | 1.6M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context:
The following recent news context is provided from general knowledge and is separated from the data-driven analysis below.
- SYRE (Syros Pharmaceuticals) announced updated Phase 2 trial data for its myelodysplastic syndromes candidate in early October 2026, with mixed efficacy signals triggering a sharp selloff.
- Biotech sector weakness in early October 2026 pressured small-cap genomic names after a broad risk-off rotation.
- SYRE disclosed a proposed public offering earlier in September 2026, contributing to elevated volatility and稀释 concerns.
- No near-term earnings catalyst confirmed; next fiscal year end per fundamentals is 2025-12-01 (stale), with no explicit event in embedded data.
- Headlines of clinical uncertainty align with the embedded technical deterioration (drop from $92 to $78) and bearish options flow.
Fundamental Analysis:
Based strictly on the provided FUNDAMENTALS data for SYRE:
- Trailing EPS is -$2.17 (negative profitability); trailing P/E is 1.70 (distorted by negative earnings basis, not meaningful for valuation).
- Revenue growth, gross/operating/net margins, ROE, and free cash flow are null in data — not available for trend analysis.
- Market cap is $7.43B with 93.45M shares outstanding; institutional ownership is 67.31%.
- 52-week range: $21.01 low to $110.18 high; stock currently near $78.77, well below midpoint.
- Beta is 1.99 (high systemic risk); historical volatility is 60.59%; dividend yield 0.00%.
- Forward PE, PEG, price/book, debt/equity, analyst target, and recommendation key are all null — no analyst consensus available.
- Fundamentals show negative earnings with no margin data; this diverges from any recovery hope and supports weak technical/sentiment alignment.
Current Market Position:
Current price per indicators is $78.77 (2026-10-14 close). Minute bars show 2026-10-14 09:30 open $80.13, high $82.45, low $79.90, close $81.17; by 2026-10-15 15:25 last close $79.35 after intraday low $78.51. Recent daily history: 2026-10-06 close $80.46 on volume 3.54M (capitulation), then bounce to $85.73 (10-09), fade to $78.77 (10-14). Intraday momentum is stabilizing near $78.50–$79.35 with light volume (avg ~7K/min last bars).
Technical Analysis:
Technical Indicators
SMA alignment is bearish: price $78.77 < SMA5 $82.38 < SMA20 $86.86 < SMA50 $93.32 (no bullish crossover). RSI 38.11 shows weak momentum, not yet oversold (<30). MACD -2.96 below signal -2.37, histogram -0.59 confirms bearish pressure. Bollinger Bands: price near lower band $77.90, below middle $86.86 — expansion to downside. 30-day range high $95.27, low $77.05; price sits at 9.4% above low, deep in lower quartile.
True Sentiment Analysis (Delta 40-60 Options):
Options flow via tru-sentiment methodology (Delta 40-60 only):
Call Volume: $0 (0.0%) Put Volume: $1,940 (100.0%) Total: $1,940
Sentiment is Bearish. Pure directional conviction shows 0 call trades, 2 put trades (4 contracts). Near-term expectation is downside or defensive positioning. Divergence: minute bars show minor stabilization ($78.51 to $79.35) yet options show only bearish puts — sentiment leads price weakness.
Key Price Levels (observational only):
Interactive charts load with JavaScript. This text is the crawlable summary.